Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%

Published on 17/03/2025 at 09:00 - Modifié on 17/03/2025 at 09:01

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Neurizon Therapeutics Limited

Neurizon Therapeutics Receives US FDA Support to Lift Clinical Hold on ALS Trial	10/07	MT
Elanco Animal Health Enters Into Licensing Agreement With Neurizon for Monepantel	03/07	MT
Neurizon Therapeutics Secures License Deal With Animal Health Company; Shares Up 3%	02/07	MT
Neurizon Therapeutics Develops Oral Liquid Formulation for Amyotrophic Lateral Sclerosis Drug Candidate	26/06	MT
Neurizon Therapeutics Says High Levels of NUZ-001 Drug Candidate Cross Blood-Brain Barrier in Rodent Study	20/06	MT
NUZ-001 Shows Promise In Zebrafish Model Of Huntington's Disease	16/06	RE
Neurizon® Therapeutics Limited Announces New Preclinical Data Demonstrating Significant Neuroprotective Effects of Nuz-001 Sulfone	16/06	CI
Neurizon Therapeutics Limited Announces Change of Registered Office and Principal Place of Business Address	02/06	CI
Neurizon Reports No Adverse Events as Final Patient Completes Sclerosis Drug Trial; Shares Fall 4%	05/05	MT
Neurizon Therapeutics Appoints Don O'Connell as Chief Financial Officer; Shares Down 4%	22/04	MT
Neurizon Therapeutics Appoints Dan O'Connell As CFO	22/04	RE
Neurizon Therapeutics Limited Appoints Dan O'Connell as Chief Financial Officer	22/04	CI
Neurizon Therapeutics Makes Three Executive Appointments; Shares Up 15%	17/04	MT
Neurizon Therapeutics Completes Study of Drug Candidate on Mouse Motor Neuron Cell Line	04/04	MT
Neurizon Therapeutics Limited Announces Results from an Additional Independent Study Carried Out in Partnership with the University of Queensland	04/04	CI
Neurizon Therapeutics Limited Announces Results from an Independent Study Conducted in Collaboration with Tessara Therapeutics	01/04	CI
ASX Biggest Gainers	28/03	MT
Neurizon Therapeutics Limited(ASX:NUZ) dropped from S&P/ASX Emerging Companies Index	24/03	CI
Neurizon Therapeutics Limited Provides Update on Preparation for Entry into the Healey & AMG Center	24/03	CI
Neurizon Therapeutics Moves to Lift FDA Suspension on NUZ-001 Drug Candidate with Two Studies; Shares Fall 5%	17/03	MT
Neurizon Therapeutics Logs HY Loss Attributable A$7.3 Mln	17/02	RE
Neurizon Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2024	17/02	CI
Neurizon Therapeutics Says Got Guidance From FDA Placing IND Application For NUZ-001 Under Clinical Hold	17/02	RE
Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%	05/02	MT
Neurizon Therapeutics Says US Patent Granted For NUZ-001	05/02	RE

NEURIZON THERAPEUTICS LIMITED

Stock

NUZ

AU0000357261

Market Closed - Australian S.E. Other stock markets 11:40:05 16/07/2025 am IST
0.1550 ^AUD	-3.12%

More quotes

Chart

Duration

Period

NUZ: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

The Week's Biggest Mergers Unpacked

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 06:59 pm IST

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 06:53 pm IST

Rare earths: Apple joins the industrial front supported by the Pentagon

July 16, 2025 at 03:46 pm IST

Is Scott Bessent the ideal candidate to succeed Jerome Powell?

July 16, 2025 at 03:36 pm IST

Rio Tinto posts strongest iron ore output since 2018 amid executive shake-up

July 16, 2025 at 01:38 pm IST

What if we already knew the name of Apple's next CEO?

July 16, 2025 at 12:51 pm IST

A Scandinavian consortium acquires Dalata for EUR1.4bn

July 15, 2025 at 07:34 pm IST

Mexican tomatoes: Made in the USA or higher prices, the Trump dilemma

July 15, 2025 at 07:26 pm IST

Meta to spend hundreds of billions on data centers

July 15, 2025 at 04:30 pm IST

All our articles